AARHUS UNIVERSITY

Press release

Please fill in this form and return it to graduateschoolhealth@au.dk in Word format no later than three weeks prior to your defence.

Basic information

Name: Nina Boje Kibsgaard Jensen Email: ninaboje@oncology.au.dk Phone: +45 61303329

Department of: Clinical Medicine

Main supervisor: Professor, ph.d. Kari Tanderup

Title of dissertation: "Bowel morbidity after radiochemotherapy and image-guided adaptive brachytherapy in locally advanced cervical cancer within the EMBRACE study".

Date for defence: June 12th 2020 at (time of day): 14.00 Place: Virtual defence via Zoom

Press release (Danish)

Tarm senfølger hos patienter med lokal fremskreden livmoderhalskræft behandlet med billedvejledt adaptiv strålebehandling og kemoterapi i EMBRACE I studiet.

Behandlingen af lokal fremskreden livmoderhalskræft med kombineret indvendig (brachyterapi) samt udvendig strålebehandling og kemoterapi har gennemgået en markant udvikling, og ført til betragtelig øget tumor kontrol samt overlevelsesgevinst. På trods af disse store fremskridt, er bivirkninger til behandlingen uundgåelige pga. eksponering af normalvæv herunder især tarmen. Forekomsten samt omfanget af specifikke tarm symptomer er kortlagt i en stor gruppe af 1416 patienter behandlet i et internationalt multi-center studie, EMBRACE I. Patient relaterede faktorer samt stråledosis og volumina fra den udvendige strålebehandling har betydning for eksempelvis udvikling af diarré, men også den indvendige strålebehandling er medvirkende årsag. Moderne behandlingsteknikker og optimering af stråleplaner har medført, at de store bestrålede tarm-volumina kan reduceres betydeligt, medførende potentielt nedsat risiko for udvikling af tarm-senfølgerne. Med billedvejledt monitorering, kan man sikre at selve tumoren får den foreskrevne stråledosis samtidig med at dosis til normalvæv kan nedsættes viser et nyt ph.d.-projekt fra Aarhus Universitet, Health. Projektet er gennemført af Nina Boje Kibsgaard Jensen, der forsvarer det d. 12/06-2020.

Forsvaret af ph.d.-projektet er offentligt og finder sted den 12/06 kl. 14.00 via Zoom. Adgang til forsvaret forgår via link, som kan fremsendes ved henvendelse til Nina Boje Kibsgaard Jensen via nedenstående kontaktoplysninger. Titlen på projektet er ”Bowel morbidity after radiochemotherapy and image-guided adaptive brachytherapy in locally advanced cervical cancer within the EMBRACE study”. Yderligere oplysninger: Ph.d.-studerende Nina Boje Kibsgaard Jensen, e-mail: ninaboje@oncology.au.dk, tlf. 61303329.

Bedømmelsesudvalg:
Professor, Gynækolog, Ingvild Vistad, Department of Clinical Sciences Haukeland Universitetssykehus, Laboratoriebygget, Bergen, Norge.

Lektor, Klinisk Onkolog, Susan Lalondrelle, Department of Radiotherapy, Royal Marsden NHS Foundation Trust London, Storbritanien.

Professor, DMSci, Søren Laurberg, Institut for Klinisk Medicin - Mave- og Tarmkirurgi, Aarhus Universitetshospital, Aarhus, Danmark.

Press release (English)

"Bowel morbidity after radiochemotherapy and image-guided adaptive brachytherapy in locally advanced cervical cancer within the EMBRACE study".

The standard of care for locally advanced cervical cancer includes external beam radiotherapy (EBRT), concomitant weekly cisplatin followed by MRI-guided brachytherapy (MR-IGABT), a combined treatment that has evolved significantly during the last few decades with increased tumour control and survival. Despite these major advancements, long-term complications to treatment occur due to the inevitable normal tissue exposure especially of the bowel. Incidences and manifestation patterns over time of specific bowel symptoms have been investigated in a large group of 1416 patients treated within the international multi-center study, EMBRACE I. Patient-related factors, radiation dose and large EBRT volumes are associated to the development of e.g. diarrhea, but also the brachytherapy contribution. With todays advanced treatment techniques and optimization of dose-plans, the large volumes of bowel irradiated may be reduced markedly and consequently reduction in the risk of late effects. With image-guided monitorering of the target during treatment, tumor dose coverage can be secured while being able to reduce the dose to normal tissue. The project was carried out by Nina Boje Kibsgaard Jensen, who is defending her dissertation on 12/06-2020.

The defence is public and takes place on 12/06 at 2:00 PM on Zoom. The title of the project is "Bowel morbidity after radiochemotherapy and image-guided adaptive brachytherapy in locally advanced cervical cancer within the EMBRACE study". For more information and for access to Zoom, please contact PhD student Nina Boje Kibsgaard Jensen, email: ninaboje@oncology.au.dk, Phone +45 61303329.

Assessment committee:
Professor Ingvild Vistad, Consultant in Obstetrics and Gynecology, Department of Clinical Sciences Haukeland Universitetssykehus, Laboratoriebygget, Bergen, Norway.

Associate professor, Susan Lalondrelle, Consultant in Clinical Oncology, Department of Radiotherapy, the Royal Marsden NHS Foundation Trust London, United Kingdom.

Professor Søren Laurberg, DMSci, Consultant Surgeon, Department of Clinical Medicine - The Department of Surgical Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.

Permission

By sending in this form:

- I hereby grant permission to publish the above Danish and English press releases.
- I confirm that I have been informed that any applicable inventions shall be treated confidentially and shall under no circumstances whatsoever be published, presented or mentioned prior to submission of a patent application, and that I have an obligation to inform my head of department and the university's Patents Committee if I believe I have made an invention in connection with my work. I also confirm that I am not aware that publication violates any other possible holders of a copyright.